Gain of Function and the Congressional Record

Part I of this series followed the federal money downstream — from the Treasury into hospital coffers and into patients' bodies. Part II followed it upstream to the Wuhan Institute of Virology and the documented compliance failures that produced the May 2024 federal suspension and proposed debarment of EcoHealth Alliance and its principal investigator. Part III sits between them. It examines the regulatory framework that was supposed to govern the upstream research, the testimony that the Director of the National Institute of Allergy and Infectious Diseases provided to the United States Senate about that research, and the documented contradictions between that testimony and NIH's own subsequent administrative acknowledgments. It examines what 18 U.S.C. § 1001 — the federal statute prohibiting false statements to Congress — provides, and what it does not provide. It examines what the Department of Justice has done with the referrals submitted to it, and what it has not done. And it examines what the people of the United States can do when the institutions whose authority depends on the documentary record decline to act on what the record establishes.

This is the part of the series in which the question shifts from what happened to what happens when nothing happens. The documentary record of compliance failures, of undisclosed conflicts, of contradicted testimony, has been published. The institutional response, to date, has been administrative sanction of one organization and one principal investigator. No criminal charges have been brought against any individual in connection with the testimony pattern. The five-year statute of limitations under 18 U.S.C. § 1001 closed for the most prominent denial in May of 2026 — last month, as this article goes to press.

What follows is the documentary record of how Congressional oversight functioned, and did not function, in the period from October 2014 through May 2026 — and what remains procedurally available to those who believe the institutional response has been insufficient.

What Gain of Function Research Actually Is

The phrase "gain-of-function research" has been used in public discourse during and after the COVID-19 pandemic with varying degrees of precision. Before examining the testimony pattern, it is necessary to establish what the phrase technically means, what its narrower regulatory definition is, and why the difference between the technical definition and the regulatory definition is the documentary fulcrum on which this part turns.

The operational scientific definition

In the broadest scientific usage, "gain-of-function" refers to any laboratory technique that enhances a biological property of a pathogen relative to its parent strain — including its transmissibility, its virulence, its host range, its ability to evade immune responses, or any other measurable property relevant to its capacity to cause disease. The phrase is descriptive, not necessarily pejorative. Many gain-of-function experiments are conducted for legitimate scientific reasons, including basic biology research and the development of vaccines and therapeutics.

The category of gain-of-function research that has occasioned public-policy controversy since approximately 2011 is more specific. It is research in which the enhanced functional property is one that increases the pathogen's potential to cause a public-health emergency in humans — typically, enhanced respiratory transmissibility or enhanced virulence in mammalian hosts that serve as proxies for human disease.

The 2011 and 2012 publications by virologists Yoshihiro Kawaoka of the University of Wisconsin and Ron Fouchier of the Erasmus Medical Center, in which laboratory techniques were used to produce H5N1 influenza viruses with enhanced transmissibility in ferrets, are the contemporary foundation of the policy debate. The Kawaoka and Fouchier papers were initially submitted to Nature and Science, were temporarily delayed at the recommendation of the U.S. National Science Advisory Board for Biosecurity, and were eventually published in modified form. The institutional debate that followed produced two organized scientific positions: the Cambridge Working Group, formed in 2014 to advocate for stricter oversight of gain-of-function research; and Scientists for Science, formed in opposition to advocate for continued research without enhanced restrictions.

The regulatory definition

The federal regulatory framework adopted a narrower definition. The 2014 White House Office of Science and Technology Policy pause statement, examined in detail in Part II of this series, applied specifically to "selected gain-of-function research projects that may be reasonably anticipated to confer attributes to influenza, MERS, or SARS viruses such that the resulting virus would have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route."

The December 2017 lifting of the pause, accompanied by the establishment of the P3CO (Potential Pandemic Pathogen Care and Oversight) Framework, narrowed the regulatory definition further. The P3CO framework defined the category of research subject to formal HHS-level review as "gain-of-function research of concern" involving a pathogen that had been pre-determined to constitute a "potential pandemic pathogen" within a specific regulatory meaning, and where the proposed research could reasonably be expected to enhance the pathogen's transmissibility or virulence.

The structural feature of the P3CO definition that becomes consequential in the testimony record is the requirement of pre-determination. The framework required that the pathogen have been formally identified as a "potential pandemic pathogen" before the gain-of-function definition was triggered. Research involving pathogens that had not been formally pre-determined to be PPPs — including bat coronaviruses that, prior to the COVID-19 pandemic, had not been formally classified as PPPs notwithstanding their phylogenetic relationship to SARS-CoV-1 — could be characterized as falling outside the formal regulatory definition even where the work would meet the operational scientific definition of gain-of-function research.

Fauci's documented institutional position before COVID

The Director of the National Institute of Allergy and Infectious Diseases held a documented institutional position on gain-of-function research that predates the COVID-19 pandemic by eight years. On July 30, 2012, in the journal mBio (the open-access journal of the American Society for Microbiology), Anthony Fauci co-authored an op-ed titled "Research on Highly Pathogenic H5N1 Influenza Virus: The Way Forward." The op-ed addressed the policy debate that the Kawaoka and Fouchier ferret-transmission experiments had produced.

The op-ed's central argument was that gain-of-function research produces public-health benefits that justify its risks. The operative passage reads:

Important information and insights can come from generating a potentially dangerous virus in the laboratory; in fact, the [gain-of-function] approach can be a critical component of developing the optimal vaccine and other measures to defend against pathogens like the H5N1 influenza virus.Anthony S. Fauci et al., "Research on Highly Pathogenic H5N1 Influenza Virus: The Way Forward," mBio (July 30, 2012)

The institutional context of the op-ed is significant. Fauci was, at the time of its publication, the Director of NIAID — the federal agency that funded a substantial portion of U.S. gain-of-function research. The op-ed was not a personal scientific opinion offered in isolation. It was a public statement by the senior federal official whose agency's funding decisions would, over the following decade, shape the practical operation of the gain-of-function research enterprise.

What the 2012 op-ed establishes for purposes of this article is that Fauci publicly defended gain-of-function research as a category, by name, before the federal pause was imposed in 2014. The institutional position he articulated in 2012 is the position that, as Part II of this series documented, NIAID applied throughout the 2014–2017 pause period when characterizing the EcoHealth Alliance grant work as outside the pause's scope.

The Two Senate Exchanges

The documentary heart of this part is two Senate hearings, conducted approximately ten weeks apart, in which Senator Rand Paul of Kentucky — a physician by training — questioned Anthony Fauci about whether NIH had funded gain-of-function research at the Wuhan Institute of Virology. The exchanges occurred before the Senate Health, Education, Labor and Pensions Committee. They are preserved in the public record by the Senate's official transcripts, by C-SPAN's video archive, and by the Congressional Record.

May 11, 2021

The first exchange occurred on May 11, 2021. Paul began with a citation to the 2017 Nature Medicine publication by Hu et al., a paper authored in part at the Wuhan Institute of Virology and supported in part by NIH funding through the EcoHealth Alliance grant, in which chimeric bat coronaviruses were constructed and characterized. Paul argued that the work described in the published paper met the operational scientific definition of gain-of-function research.

The denial was unqualified. It contained no carve-out for definitional disputes. It used the phrase "has not ever and does not now," language that addressed both the historical record and the present moment. It applied "gain-of-function research" without modifier, asserting that no NIH funding of any such research at WIV had occurred.

July 20, 2021

Ten weeks later, on July 20, 2021, the same committee. Paul returned to the question with additional documentary specificity. He cited the 2015 Nature Medicine paper by Menachery et al., conducted in part by Ralph Baric at the University of North Carolina in collaboration with Shi Zhengli of the Wuhan Institute of Virology, in which chimeric SARS-related coronaviruses were constructed in BSL-3 conditions. He cited the 2017 Hu et al. paper. He asked Fauci whether his earlier denial remained operative.

Fauci's response was a reiteration of the May 11 denial, supplemented by a definitional argument. Fauci asserted that the work described in the cited papers did not meet the formal regulatory definition of gain-of-function research because the bat coronaviruses involved had not been pre-determined to be potential pandemic pathogens. He further asserted that the technical-definitional question was the operative consideration, and that the operational scientific characterization Paul advanced was inconsistent with the regulatory framework.

Paul's response, as preserved in the transcript, included an explicit reference to 18 U.S.C. § 1001 and the prohibition against making false statements to a Senate committee. Fauci responded:

Senator Paul, I have never lied before the Congress and I do not retract that statement. This paper that you are referring to was judged by qualified staff up and down the chain as not being gain-of-function.Dr. Anthony S. Fauci, Senate HELP Committee, July 20, 2021

The exchange was televised. It was reported in major media outlets within hours. It produced, in the days that followed, a formal referral by Senator Paul to the Department of Justice for investigation of the testimony under § 1001.

The Paul referral letter

On August 4, 2021, Senator Paul sent a letter to Attorney General Merrick Garland formally referring the matter for prosecutorial review. The letter cited 18 U.S.C. § 1001 and identified the May 11 and July 20 testimony as potentially false statements within the meaning of the statute. The letter was made public the same day.

The Department of Justice did not, in the period that followed, publicly acknowledge action on the referral. No grand jury was convened. No indictment was sought. No public statement was issued by the Attorney General's office addressing the substantive question of whether the testimony fell within the statute's scope.

The institutional silence is itself part of the documentary record.

The Tabak Letter

Three months after the second Senate denial — on October 20, 2021 — NIH Principal Deputy Director Lawrence Tabak sent a letter to Representative James Comer, then ranking member of the House Committee on Oversight and Reform. The letter was on NIH letterhead. It was signed by the Number Two official at NIH. It addressed the EcoHealth Alliance grant directly.

The letter's operative passage read in part:

EcoHealth Alliance, Inc. did include this requirement in its sub-award to WIV. As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do. Regardless, the grantee has now submitted the [Year Five] progress report to NIH. The NIH is examining the report and will determine whether additional acts need to be taken. . . . [In the experiments] humanized mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus.Letter from NIH Principal Deputy Director Lawrence A. Tabak to Representative James Comer, October 20, 2021

Translated from the regulatory prose: NIH's own Principal Deputy Director, in writing, on official letterhead, acknowledged three things. First, that the EcoHealth grant had funded experiments in which a chimeric bat coronavirus — SHC014 WIV1 — was constructed in the laboratory. Second, that the chimeric virus produced more severe disease in humanized mice than the parent strain. Third, that EcoHealth had been required to report this result within two years of its occurrence and had not done so within the required timeframe.

The substantive contradiction with the May and July testimony was documentary. Fauci had testified that NIH had not ever and does not now fund gain-of-function research at WIV. NIH's Principal Deputy Director, three months later, in writing, acknowledged that NIH had funded research at WIV in which experimental chimeric viruses caused enhanced disease in mammalian models — the operative scientific definition of gain-of-function research that the 2014 federal pause had been designed to address.

The Tabak letter did not characterize the experiments as falling within the formal P3CO regulatory definition. The letter's framing maintained the position that the work had not required P3CO referral. But the letter could not avoid the substantive acknowledgment that, in operational scientific terms, the funded research had produced enhanced disease properties in a chimeric virus.

This is the documentary record of how Congressional oversight produced, in a period of three months, an exchange in which the Director of NIAID denied funding gain-of-function research at WIV and the Principal Deputy Director of NIH acknowledged funding research that, in operational scientific terms, met the definition Fauci had denied.

The Definitional Defense and Its Limits

The defense Fauci has articulated, repeatedly, in subsequent public commentary and in his January 2024 transcribed interview before the House Select Subcommittee on the Coronavirus Pandemic, is technically articulable. The argument runs as follows.

The phrase "gain-of-function research" has, in the federal regulatory context, a specific meaning defined by the P3CO Framework. Under that framework, "gain-of-function research of concern" refers to research involving a pathogen pre-determined to constitute a "potential pandemic pathogen" within the meaning of the framework's definitional language. The bat coronaviruses involved in the EcoHealth grant work had not been pre-determined to be PPPs. Therefore, under the formal regulatory definition, the work was not "gain-of-function research of concern" requiring P3CO referral, and was not "gain-of-function research" within the meaning Fauci's testimony addressed.

The defense is technically articulable. It is also subject to substantive critique that has been advanced, repeatedly and publicly, by senior virologists with documented credentials and no apparent partisan motivation.

The Ebright critique

Richard Ebright is a Board of Governors Professor of Chemistry and Chemical Biology at Rutgers University. His published work on bacterial transcription is among the most cited in the field. He is not a partisan investigator. He is, by any institutional measure, one of the senior credentialed voices in U.S. molecular biology.

Ebright has stated, repeatedly and publicly, that the experiments described in the Tabak letter meet the operational scientific definition of gain-of-function research, and that the technical-definitional argument advanced in defense of the May and July 2021 testimony is, in his assessment, inconsistent with the public meaning of the phrase. In a series of public statements, including testimony before Congressional committees, Ebright has characterized the definitional defense as a regulatory artifact that does not address the substantive scientific question.

The Relman position

David Relman is a Professor of Medicine and of Microbiology and Immunology at Stanford University. He served on the National Science Advisory Board for Biosecurity. He has published extensively on biosafety and biosecurity policy. He has stated publicly that the P3CO Framework, as administered, has been administered in a manner that frustrates rather than serves its statutory purpose. He has further stated that the definition of "gain-of-function research of concern" used by NIAID to characterize the EcoHealth grant work was, in his assessment, applied in a manner that produced the conclusion the agency wished to reach.

The Lipsitch position

Marc Lipsitch is a Professor of Epidemiology at the Harvard T.H. Chan School of Public Health. He was a founding member of the Cambridge Working Group. He has published extensively on infectious disease epidemiology and on biosafety policy. His critique of the P3CO Framework's administration during the period covered by the EcoHealth grant has been substantively similar to those of Ebright and Relman.

The structural question

What the convergence of these credentialed scientific voices establishes is that the definitional defense advanced in support of the May and July 2021 testimony is not unanimously accepted within the relevant scientific community. Senior virologists with documented credentials and no apparent partisan motivation have characterized the defense as inconsistent with the operational scientific definition of the term and with the public meaning that a Senator and a viewing public would reasonably attribute to the phrase.

This raises a structural question that 18 U.S.C. § 1001 was, in part, designed to address. When a witness testifies before Congress using a technical regulatory definition known principally to specialists, while the questioner and the public understand the same phrase in its operational scientific meaning, has the witness provided accurate testimony, or has the witness exploited definitional ambiguity to convey a false impression?

The federal courts have addressed analogous questions. In United States v. Bronston, 409 U.S. 352 (1973), the Supreme Court held that a literally true but misleading statement does not constitute perjury under 18 U.S.C. § 1621. But the Court has also held, in subsequent cases addressing 18 U.S.C. § 1001, that a statement may be false within the meaning of § 1001 if it is "materially" false — that is, if it conveys a false impression to the questioner that is reasonably calculated to deceive, even where the statement is technically defensible under a narrow definitional construction. The materiality standard under § 1001 is not identical to the literal-truth standard under § 1621.

Whether the May 11 and July 20, 2021 testimony falls within § 1001's materiality standard is a question that, as a matter of formal legal determination, can only be made by a federal grand jury and, ultimately, a federal jury. No such determination has been made. What this article asserts, and what the documentary record establishes, is that the question was raised by a Senator who is also a physician, was the subject of a formal referral to the Department of Justice, and has been substantively criticized by senior credentialed scientists who have characterized the definitional defense as inconsistent with the operational scientific meaning of the phrase.

The January 2024 Transcribed Interview

In January 2024, the House Select Subcommittee on the Coronavirus Pandemic conducted a fourteen-hour transcribed interview of Anthony Fauci, over two days — January 8 and January 9, 2024. The format of a transcribed interview is, in Congressional investigative practice, an unusual milestone. It is conducted under penalty of false statements under 18 U.S.C. § 1001, in the same manner as testimony before a public hearing. It produces a complete verbatim transcript that becomes part of the documentary record.

The Subcommittee's questioning addressed the full scope of the testimony pattern. The EcoHealth grant. The gain-of-function definitional question. The February 1, 2020 conference call examined in Part II of this series. The Proximal Origin paper. The Lancet letter. The compliance failures that would, four months later, become the basis for the May 2024 suspension and proposed debarment.

In April 2024, the Subcommittee released a memorandum summarizing the interview's findings. The Memorandum identified specific points at which the Subcommittee found Fauci's responses unsatisfactory or inconsistent with the documentary record. The Subcommittee's findings were not partisan conclusions advanced over partisan dissent. The bipartisan record of the Subcommittee's investigative work, including testimony from career federal officials and review of FOIA-released communications, supported the documentary findings.

The institutional significance of the January 2024 interview cannot be reduced to its outcome. A fourteen-hour interview is not undertaken in the absence of substantial documentary basis for the questioning. The transcript itself, in its volume and specificity, constitutes a record of the Subcommittee's view that the testimony pattern warranted detailed examination. Whether that examination has produced, or will produce, formal action under 18 U.S.C. § 1001 or other statutes is a separate question, addressed in the next section.

The Statute of Limitations and the Prosecutorial Discretion Question

18 U.S.C. § 1001 makes it a federal crime, punishable by up to five years' imprisonment, to knowingly and willfully make a materially false statement in any matter within the jurisdiction of the executive, legislative, or judicial branch of the United States government. Statements made under oath to a Congressional committee fall within the statute's scope. Statements made in transcribed interviews conducted under penalty of false statements fall within the statute's scope.

The statute of limitations for § 1001 violations is five years from the date of the false statement. The institutional clock runs from the moment the statement is made, not from the moment it is investigated or referred for prosecution.

The relevant clocks

The May 11, 2021 testimony's window has closed. The window closed in May 2026 — last month, as this article goes to press. The Department of Justice did not, during the five-year window during which formal action remained available under § 1001, bring charges against any individual in connection with that statement. The statute of limitations is, as a matter of federal criminal procedure, a jurisdictional bar. Charges that could have been brought during the open window cannot be brought now.

The July 20, 2021 testimony's window remains open as of the publication of this article. It will close in July 2026 — approximately two months from the date of this writing.

The January 2024 transcribed interview's window remains open through January 2029. Whatever the DOJ may decide about the 2021 testimony, the 2024 interview record remains within the statutory window for formal action through the end of the current decade.

The prosecutorial discretion question

Federal prosecution of senior officials for testimony to Congress is, historically, rare. The institutional precedent runs in both directions. In 2007, Lewis "Scooter" Libby, former Chief of Staff to Vice President Dick Cheney, was convicted of perjury and false statements arising from his testimony in the investigation of the Valerie Plame disclosure. His sentence was commuted by President George W. Bush; he was later pardoned by President Donald Trump in 2018. In 2012, baseball player Roger Clemens was acquitted of perjury charges arising from his Congressional testimony about performance-enhancing drug use. In 2024, FBI informant Alexander Smirnov was charged with making false statements to FBI agents in connection with information he provided to the Bureau, illustrating that prosecutions for false statements in federal investigative contexts continue.

The institutional record of § 1001 prosecutions of senior federal officials for testimony to Congress is sparse. The reasons are several. Prosecutorial discretion considerations include the difficulty of proving the "knowingly and willfully" mental state to the satisfaction of a unanimous jury; the materiality determination, which courts review carefully; the institutional reluctance of the Department of Justice to prosecute senior officials whose conduct may be characterized as policy disagreement rather than criminal misrepresentation; and the political dimension of any prosecution touching on the conduct of a senior agency director.

The structural question is whether the rarity of § 1001 prosecutions for Congressional testimony reflects the rarity of false statements that warrant prosecution, or reflects an institutional architecture in which the practical accountability for such statements is administrative rather than criminal.

The November 2024 House Select Subcommittee final report referred multiple individuals, including Fauci, to the Department of Justice for further investigation. The transition to the second Trump administration in January 2025, with Pam Bondi's confirmation as Attorney General in February 2025, produced a public posture of openness to investigation of cases that were pending but had not been acted upon under the prior administration. As of the date of this article, no public charging document under § 1001 has been filed. Whether the DOJ acts on the Subcommittee's referrals during the open windows that remain — through July 2026 for the 2021 testimony and through January 2029 for the 2024 interview — is a question that the public record does not yet answer.

This article does not assert that prosecution should occur. The decision whether to prosecute is a matter of executive-branch discretion exercised under the constitutional separation of powers. What this article asserts, and what the documentary record establishes, is that the statutory windows have run, are running, and will close on a fixed schedule that the prosecutorial machinery either acts within or it does not.

The International Counterpart — and Why Geneva Cannot Substitute

The federal regulatory framework that was supposed to govern gain-of-function research has an international counterpart, and the failure of the international counterpart is a documentary point worth recording briefly here.

The International Health Regulations (2005), administered by the World Health Organization, are the principal multilateral instrument governing the international response to public-health emergencies of international concern. The IHR (2005) requires member states to develop and maintain the public-health capacities necessary to detect, assess, report, and respond to such emergencies. The IHR (2005) does not, however, contain meaningful international biosafety oversight provisions. There is no WHO-administered international counterpart to the U.S. P3CO Framework. There is no multilateral body that reviews and approves or declines to fund gain-of-function research at the international level.

The Wuhan Institute of Virology, where the EcoHealth grant subaward research was conducted, operated under Chinese regulatory authority. The People's Republic of China has its own biosafety framework, with provisions that have been the subject of substantial international scrutiny but that operated, throughout the period covered by the EcoHealth grant, without meaningful international coordination with the U.S. P3CO process.

The WHO's institutional posture on the origin question, the Tedros Adhanom Ghebreyesus statement of February 2022 reopening the origin investigation following the inconclusive findings of the WHO-convened January-February 2021 study mission to Wuhan, and the broader question of how the WHO has functioned during the pandemic period are matters this series will examine in detail in a separate investigative project. They are noted here only to establish that the gap in the international regulatory architecture is a documentary fact, not a hypothetical concern.

What the international gap means for the present analysis is straightforward. The United States cannot rely on multilateral institutions to enforce the standards that the U.S. domestic framework was designed to enforce. The accountability question raised by the testimony pattern is, at its operational level, a domestic question. The institutions whose conduct is at issue are U.S. federal institutions. The statute under which formal action remains available is U.S. federal law. The mechanisms through which the people of the United States can act on the documented record are domestic mechanisms. The international architecture, whatever its merits, is not the answer.

The Pattern Across Three Parts

Read together, Parts I, II, and III of this series document the architecture of an institutional system in which the same federal scientific agency funded the upstream research, sponsored the downstream trial, drafted the protocol that became hospital practice, designed the financial incentives that drove administration, and provided the testimony to Congress about all of it.

The architectural concentration is documented in the public record. It is not a matter of inference. The same agency. The same Director. The same institutional position. The funding decisions in 2014 and again in 2019 that supplied the EcoHealth Alliance grant. The communications in February 2020 that influenced the institutional posture toward pandemic origin. The trial design in February through April 2020 that produced the regulatory authorization for remdesivir. The protocol decisions through 2021 and beyond that shaped hospital practice. The testimony in May and July 2021 that addressed the funding question. The transcribed interview in January 2024 that addressed the full pattern.

What independent oversight existed at each stage of this architecture? The federal pause of 2014 was administered by the same agencies whose research it was supposed to constrain. The P3CO Framework after 2017 referred review decisions back to the same agencies whose grants would be affected. The Congressional oversight function depended on testimony provided by the same agency officials whose conduct was at issue. The False Claims Act and 18 U.S.C. § 1001, the legal sanctions of last resort, depended on prosecutorial discretion exercised by a Department of Justice operating within the same federal executive branch.

The structural finding is not that any single individual designed the system to fail. It is that the system, as designed, did not contain the independent checks that the regulatory framework was supposed to provide. The check that was supposed to function was Congressional oversight, supplemented by 18 U.S.C. § 1001 as the legal sanction against testimony that diverges from documentary record. The check that has functioned, to date, has produced an extensive documentary record but no formal action against any individual under the statute.

What the People of the United States Can Do

The institutional response to the documentary record, as of May 2026, has been administrative. The HHS suspension and proposed debarment of EcoHealth Alliance and Peter Daszak in May of 2024. The Senate and House investigative reports. The FOIA releases. The Department of Justice has not, to date, brought charges against any individual in connection with the testimony pattern documented in Sections II through V of this article. Whether it will, during the windows that remain open, is a question the documentary record does not yet answer.

What follows is a documentary catalog of the procedural avenues that remain available to the people of the United States who believe that the institutional response has been insufficient. The catalog is observational, not directive. The mechanisms are real. Their effectiveness depends on use. None of them is a substitute for the institutional accountability mechanisms that have not, to date, produced charges. All of them are part of the architecture by which a self-governing people maintains the institutions that purport to govern in its name.

The catalog above is not exhaustive. It is a starting point. Each mechanism has its own procedural requirements, its own institutional pathway, its own probability distribution of outcomes. Each is, in the present moment, procedurally available to the people of the United States. None requires a license, a credential, or a position of institutional authority. All require the willingness to use them.

The accountability infrastructure of a self-governing republic is not constructed exclusively by the institutions designated to administer it. It is constructed, in significant part, by the citizens who choose to use the procedural avenues that exist. The institutional record establishes that the formal accountability mechanisms — the Department of Justice, the executive-branch enforcement bodies, the inspectors general — have produced an administrative response and a documentary record but have not, to date, produced personal accountability for the testimony pattern. The question of what comes next is not, in the architecture of American constitutional government, a question reserved exclusively for those institutions. It is a question that, by design, citizens may answer through the mechanisms enumerated above.

The next part of this series, Part IV, will examine the information environment within which the institutional response was shaped — the relationship between legacy media, social-media platforms, federal agencies, and the institutional architecture documented in Parts I, II, and III. That information environment, the Fauci Files will document, was not a passive observer of the institutional response. It was an active participant in shaping the response, with documented financial relationships, documented coordination with federal agencies, and documented conduct that the public record now substantially establishes.

This part has documented the testimony. The next will document the environment within which the testimony was received, characterized, and — in significant part — protected from the documentary record that has now, in May of 2026, become the unavoidable subject of any honest assessment of the pandemic-era institutional response.

The documentary record speaks. The institutions whose authority depends on that record have not yet spoken in turn. The people of the United States, whose authority is logically prior to that of the institutions that operate in their name, retain the procedural avenues to insist that they do.